07.08.2015 • NewsBoehringer IngelheimDede Willamsgenerics

Boehringer Selling US Generics Arm to Hikima

Boehringer Ingelheim, the German drugmaker, has sold its US generics business for $2.7 billion to London-based Jordanian-British owned Hikima Pharmaceuticals. At the same time, it has taken a 6.7% stake in the company. 

The acquisition price for Roxane is $1.2 billion, but Boehringer is also picking up $40 million in Hikima shares along with milestone payments of up to $125 million.

Nucleus of the German company’s generics arm is Roxane, based in the US state of Ohio. The firm produces and markets generic versions of Boehringer’s products, along with some of its

In 2014, Hikima bought Boehringer subsidiary Bedford Laboratories, which manufactures injectables.

 

 

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.